Pdb43 - The Costs and Results of Incretins’and SGLT-2i Diabetes Therapy in Bulgaria

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.748
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

SGLT-2 Inhibitors and Their Potential in the Treatment of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Pdb44 - The Health Economic Value of Short-Term Cardiovascular Benefits Associated With SGLT-2i From CVD-Real

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

Metabolic Syndrome and Related Disorders
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Budget Impact Analysis of Adding Dapaglifozin to the Therapy of Diabetes Mellitus Type 2 in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Psy88 - Pharmacotherapy Costs for Patients With Acromegaly in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effect of SGLT in Type 2 Diabetes and Gastric Bypass Surgery - A Narrative Review

International Journal of Contemporary Medical Research [IJCMR]
2019English

Direct Costs of Diabetes Mellitus in Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Societal Costs of Diabetes Mellitus in Denmark

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

The Costs of Drug Prescriptions for Diabetes in the NHS

The Lancet
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy